Traitement en cours

Veuillez attendre...

PATENTSCOPE sera indisponible durant quelques heures pour des raisons de maintenance le dimanche 05.04.2020 à 10:00 AM CEST
Paramétrages

Paramétrages

1. WO2012009387 - FORMULATIONS DE RIFAXIMINE ET UTILISATIONS CORRESPONDANTES

Numéro de publication WO/2012/009387
Date de publication 19.01.2012
N° de la demande internationale PCT/US2011/043767
Date du dépôt international 12.07.2011
CIB
C07D 498/00 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
DCOMPOSÉS HÉTÉROCYCLIQUES
498Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle
CPC
A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 47/32
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers ; , poly(meth)acrylates, or polyvinyl pyrrolidone
A61K 47/38
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
38Cellulose; Derivatives thereof
A61K 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
A61K 9/146
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
146with organic macromolecular compounds
A61K 9/1641
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1629Organic macromolecular compounds
1641obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
Déposants
  • SALIX PHARMACEUTICALS, LTD [US/US]; 1700 Perimeter Park Drive Morrisville, NC 27560, US (AllExceptUS)
  • SELBO, Jon [CN/US]; US (UsOnly)
  • TENG, Jing [CN/US]; US (UsOnly)
  • KABIR, Mohammed, A. [US/US]; US (UsOnly)
  • GOLDEN, Pam [US/US]; US (UsOnly)
Inventeurs
  • SELBO, Jon; US
  • TENG, Jing; US
  • KABIR, Mohammed, A.; US
  • GOLDEN, Pam; US
Mandataires
  • SPARKS, Jonathan, M.; McCarter & English, LLP 265 Franklin Street Boston, MA 02110, US
Données relatives à la priorité
61/363,60912.07.2010US
61/419,05602.12.2010US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) FORMULATIONS OF RIFAXIMIN AND USES THEREOF
(FR) FORMULATIONS DE RIFAXIMINE ET UTILISATIONS CORRESPONDANTES
Abrégé
(EN)
The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.
(FR)
L'invention concerne de nouvelles formes de rifaximine comprenant des dispersions solides de rifaximine, des procédés de préparation de celles-ci ainsi que leur utilisation dans des préparations médicamenteuses et des méthodes thérapeutiques.
Dernières données bibliographiques dont dispose le Bureau international